Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Clinuvel Pharmaceuticals ( (AU:CUV) ) has issued an update.
Clinuvel Pharmaceuticals Limited has announced the quotation of 58,627 ordinary fully paid securities on the Australian Securities Exchange (ASX), effective from October 1, 2025. This move is part of the company’s ongoing efforts to enhance its financial flexibility and strengthen its market position, potentially impacting stakeholders by increasing the liquidity of its shares.
The most recent analyst rating on (AU:CUV) stock is a Buy with a A$13.00 price target. To see the full list of analyst forecasts on Clinuvel Pharmaceuticals stock, see the AU:CUV Stock Forecast page.
More about Clinuvel Pharmaceuticals
Clinuvel Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on developing and commercializing treatments for severe skin disorders and related conditions. The company is known for its innovative therapies, particularly in the field of photoprotection and repigmentation.
Average Trading Volume: 140,787
Technical Sentiment Signal: Sell
Current Market Cap: A$601.5M
For detailed information about CUV stock, go to TipRanks’ Stock Analysis page.